Biglycan modulates angiogenesis and bone formation during fracture healing

Matrix Biology

Volumn 35, Issue , 2014, Pages 223-231

  Berendsen, Agnes D ^a   Pinnow, Emily L ^a   Maeda, Azusa ^a   Brown, Aaron C ^a   McCartney Francis, Nancy ^a   Kram, Vardit ^a   Owens, Rick T ^b   Robey, Pamela G ^a   Holmbeck, Kenn ^a   de Castro, Luis F ^a   Kilts, Tina M ^a   Young, Marian F ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b LIFECELL CORPORATION   (United States)

Author keywords

Angiogenesis; Biglycan; Callus; Fracture healing; Mineralization

Indexed keywords

BIGLYCAN; COLLAGEN TYPE 1; VASCULOTROPIN A; PRIMER DNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALLUS; CARTILAGE; CONTROLLED STUDY; FEMUR FRACTURE; FRACTURE HEALING; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BONE DEVELOPMENT; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; RADIOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ANIMALS; BIGLYCAN; BONY CALLUS; DNA PRIMERS; FRACTURE HEALING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; X-RAY MICROTOMOGRAPHY;

EID: 84901398644     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.12.004     Document Type: Article

References (34)

1. Amenta A.R., Yilmaz A., Bogdanovich S., McKechnie B.A., Abedi M., Khurana T.S., Fallon J.R. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:762-767.
2. Amenta A.R., Creely H.E., Mercado M.L., Hagiwara H., McKechnie B.A., Lechner B.E., Rossi S.G., Wang Q., Owens R.T., Marrero E., Mei L., Hoch W., Young M.F., McQuillan D.J., Rotundo R.L., Fallon J.R. Biglycan is an extracellular MuSK binding protein important for synapse stability. J. Neurosci. 2012, 32:2324-2334.
3. Ameye L., Young M.F. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002, 12:107R-116R.
4. Barnes G.L., Kostenuik P.J., Gerstenfeld L.C., Einhorn T.A. Growth factor regulation of fracture repair. J. Bone Miner. Res. 1999, 14:1805-1815.
5. Berendsen A.D., Fisher L.W., Kilts T.M., Owens R.T., Robey P.G., Gutkind J.S., Young M.F. Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17022-17027.
6. Bianco P., Fisher L.W., Young M.F., Termine J.D., Robey P.G. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J. Histochem. Cytochem. 1990, 38:1549-1563.
7. Buraschi S., Neill T., Goyal A., Poluzzi C., Smythies J., Owens R.T., Schaefer L., Torres A., Iozzo R.V. Decorin causes autophagy in endothelial cells via Peg3. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2582-E2591.
8. Chen X.D., Shi S., Xu T., Robey P.G., Young M.F. Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J. Bone Miner. Res. 2002, 17:331-340.
9. Chen X.D., Allen M.R., Bloomfield S., Xu T., Young M. Biglycan-deficient mice have delayed osteogenesis after marrow ablation. Calcif. Tissue Int. 2003, 72:577-582.
10. Chen X.D., Fisher L.W., Robey P.G., Young M.F. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. 2004, 18:948-958.
11. Clarkin C.E., Gerstenfeld L.C. VEGF and bone cell signalling: an essential vessel for communication?. Cell Biochem. Funct. 2013, 31:1-11.
12. Corsi A., Xu T., Chen X.D., Boyde A., Liang J., Mankani M., Sommer B., Iozzo R.V., Eichstetter I., Robey P.G., Bianco P., Young M.F. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J. Bone Miner. Res. 2002, 17:1180-1189.
13. Critchlow M.A., Bland Y.S., Ashhurst D.E. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. Bone 1995, 16:521-527.
14. de Castro L.F., Lozano D., Dapia S., Portal-Nunez S., Caeiro J.R., Gomez-Barrena E., Esbrit P. Role of the N- and C-terminal fragments of parathyroid-hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng. A 2010, 16:1157-1168.
15. Delos D., Yang X., Ricciardi B.F., Myers E.R., Bostrom M.P., Camacho N.P. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J. Orthop. Res. 2008, 26:153-164.
16. Einhorn T.A. The cell and molecular biology of fracture healing. Clin. Orthop. Relat. Res. 1998, S7-S21.
17. Fisher L.W., Termine J.D., Dejter S.W., Whitson S.W., Yanagishita M., Kimura J.H., Hascall V.C., Kleinman H.K., Hassell J.R., Nilsson B. Proteoglycans of developing bone. J. Biol. Chem. 1983, 258:6588-6594.
18. Fisher L.W., Stubbs J.T., Young M.F. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop. Scand. Suppl. 1995, 266:61-65.
19. Hwang J.Y., Johnson P.Y., Braun K.R., Hinek A., Fischer J.W., O'Brien K.D., Starcher B., Clowes A.W., Merrilees M.J., Wight T.N. Retrovirally mediated overexpression of glycosaminoglycan-deficient biglycan in arterial smooth muscle cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointimae after vascular injury. Am. J. Pathol. 2008, 173:1919-1928.
20. Iozzo R.V., Goldoni S., Berendsen A.D., Young M.F. Small leucine-rich proteoglycans. The Extracellular Matrix: An Overview 2011, Springer, Berlin Keldelberg. R. Mecham (Ed.).
21. Jingushi S., Heydemann A., Kana S.K., Macey L.R., Bolander M.E. Acidic fibroblast growth factor (aFGF) injection stimulates cartilage enlargement and inhibits cartilage gene expression in rat fracture healing. J. Orthop. Res. 1990, 8:364-371.
22. Kawakatsu M., Kanno S., Gui T., Gai Z., Itoh S., Tanishima H., Oikawa K., Muragaki Y. Loss of Smad3 gives rise to poor soft callus formation and accelerates early fracture healing. Exp. Mol. Pathol. 2011, 90:107-115.
23. Manigrasso M.B., O'Connor J.P. Characterization of a closed femur fracture model in mice. J. Orthop. Trauma 2004, 18:687-695.
24. Mattsson G., Carlsson P.O., Olausson K., Jansson L. Histological markers for endothelial cells in endogenous and transplanted rodent pancreatic islets. Pancreatology 2002, 2:155-162.
25. Meganck J.A., Begun D.L., McElderry J.D., Swick A., Kozloff K.M., Goldstein S.A., Morris M.D., Marini J.C., Caird M.S. Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta. Bone 2013, 56:204-212.
26. Mercado M.L., Amenta A.R., Hagiwara H., Rafii M.S., Lechner B.E., Owens R.T., McQuillan D.J., Froehner S.C., Fallon J.R. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J. 2006, 20:1724-1726.
27. Morgan E.F., Mason Z.D., Chien K.B., Pfeiffer A.J., Barnes G.L., Einhorn T.A., Gerstenfeld L.C. Micro-computed tomography assessment of fracture healing: relationships among callus structure, composition, and mechanical function. Bone 2009, 44:335-344.
28. Nakamura T., Hara Y., Tagawa M., Tamura M., Yuge T., Fukuda H., Nigi H. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J. Bone Miner. Res. 1998, 13:942-949.
29. Nyman J.S., Makowski A.J. The contribution of the extracellular matrix to the fracture resistance of bone. Curr. Osteoporos. Rep. 2012, 10:169-177.
30. Obika M., Vernon R.B., Gooden M.D., Braun K.R., Chan C.K., Wight T.N. ADAMTS-4 and biglycan are expressed at high levels and co-localize to podosomes during endothelial cell tubulogenesis in vitro. J. Histochem. Cytochem. 2013, 62:34-49.
31. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., Krzyzankova M., Marsche G., Young M.F., Mihalik D., Gotte M., Malle E., Schaefer R.M., Grone H.J. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 2005, 115:2223-2233.
32. Tsuji K., Bandyopadhyay A., Harfe B.D., Cox K., Kakar S., Gerstenfeld L., Einhorn T., Tabin C.J., Rosen V. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat. Genet. 2006, 38:1424-1429.
33. Xu T., Bianco P., Fisher L.W., Longenecker G., Smith E., Goldstein S., Bonadio J., Boskey A., Heegaard A.M., Sommer B., Satomura K., Dominguez P., Zhao C., Kulkarni A.B., Robey P.G., Young M.F. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 1998, 20:78-82.
34. Young M.F., Fallon J.R. Biglycan: a promising new therapeutic for neuromuscular and musculoskeletal diseases. Curr. Opin. Genet. Dev. 2012, 22:398-400.